Pharmacotherapy of small cell lung cancer: Current state-of-the-art

Q3 Pharmacology, Toxicology and Pharmaceutics
T. Berezhnova, Yelena A. Lunyova, Kseniya S. Dyadina, V. Borisov
{"title":"Pharmacotherapy of small cell lung cancer: Current state-of-the-art","authors":"T. Berezhnova, Yelena A. Lunyova, Kseniya S. Dyadina, V. Borisov","doi":"10.18413/rrpharmacology.9.10001","DOIUrl":null,"url":null,"abstract":"Introduction: Lung carcinoma is the leading cause of death in men and is closely related to smoking. The article focuses on the current statistics of this pathology in the world. \nMaterials and methods: The literature review was carried out using PubMed database and included articles published from 2006 to 2021. The current schemes of chemotherapy and diagnostic options of small cell lung cancer were analyzed. The mechanisms of drug action on tumor cells were considered. An analysis of the publication activity in PubMed database related to pharmacotherapy of small cell lung cancer allows reporting a twofold increase in the number of publications over the period from 2007 to 2017. \nResults and discussion: A systematic review presenting staging of small cell lung cancer (SCLC) and its radiation diagnostics has been conducted. As demonstrated, there are no current methods with proven effectiveness to early detect this pathology. However, it has been found that annual low-dose CT screenings helped detect a significant number of lung cancer cases at the early stage, although, the proportion of small cell carcinoma is still very high. Analyses of clinical outcomes of small cell lung cancer have showed that cisplatin/etoposide (EP) or carboplatin/etoposide (EC) appear to be the key combinations with high treatment efficacy. The article also discusses chemotherapy for small cell lung cancer, namely and the principle of its effect on tumor cells. However, this chemotherapy remains very toxic and causes a number of life-threatening side effects. It is necessary to assess the effectiveness of chemotherapy immediately after the start of treatment in order to balance benefits and risks. \nConclusion: The search is currently under way for less toxic but effective compounds, this fact being a crucial issue of healthcare in providing high-quality medical and pharmaceutical care for cancer patients. Chemotherapy of the pathology under study requires high costs; therefore, a pharmacoeconomical assessment of the prescription of chemotherapy for small cell lung cancer is necessary to compare the costs of treatment and its effectiveness \nGraphical Abstract","PeriodicalId":21030,"journal":{"name":"Research Results in Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Results in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18413/rrpharmacology.9.10001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Lung carcinoma is the leading cause of death in men and is closely related to smoking. The article focuses on the current statistics of this pathology in the world. Materials and methods: The literature review was carried out using PubMed database and included articles published from 2006 to 2021. The current schemes of chemotherapy and diagnostic options of small cell lung cancer were analyzed. The mechanisms of drug action on tumor cells were considered. An analysis of the publication activity in PubMed database related to pharmacotherapy of small cell lung cancer allows reporting a twofold increase in the number of publications over the period from 2007 to 2017. Results and discussion: A systematic review presenting staging of small cell lung cancer (SCLC) and its radiation diagnostics has been conducted. As demonstrated, there are no current methods with proven effectiveness to early detect this pathology. However, it has been found that annual low-dose CT screenings helped detect a significant number of lung cancer cases at the early stage, although, the proportion of small cell carcinoma is still very high. Analyses of clinical outcomes of small cell lung cancer have showed that cisplatin/etoposide (EP) or carboplatin/etoposide (EC) appear to be the key combinations with high treatment efficacy. The article also discusses chemotherapy for small cell lung cancer, namely and the principle of its effect on tumor cells. However, this chemotherapy remains very toxic and causes a number of life-threatening side effects. It is necessary to assess the effectiveness of chemotherapy immediately after the start of treatment in order to balance benefits and risks. Conclusion: The search is currently under way for less toxic but effective compounds, this fact being a crucial issue of healthcare in providing high-quality medical and pharmaceutical care for cancer patients. Chemotherapy of the pathology under study requires high costs; therefore, a pharmacoeconomical assessment of the prescription of chemotherapy for small cell lung cancer is necessary to compare the costs of treatment and its effectiveness Graphical Abstract
小细胞肺癌的药物治疗:最新进展
引言:肺癌是男性死亡的主要原因,与吸烟密切相关。这篇文章的重点是目前世界上对这种病理学的统计。材料和方法:使用PubMed数据库进行文献综述,包括2006年至2021年发表的文章。分析了癌症小细胞肺癌的化疗方案和诊断方案。探讨了药物对肿瘤细胞的作用机制。对PubMed数据库中与小细胞肺癌癌症药物治疗相关的出版活动进行分析,可以报告2007年至2017年期间出版数量增加了两倍。结果与讨论:对癌症小细胞肺癌(SCLC)的分期及其放射诊断进行了系统综述。正如所证明的,目前还没有被证明有效的方法来早期检测这种病理。然而,人们发现,每年低剂量CT筛查有助于在早期发现大量癌症病例,尽管小细胞癌的比例仍然很高。小细胞肺癌癌症的临床结果分析表明,顺铂/依托泊苷(EP)或卡铂/依托泊苷(EC)似乎是具有高治疗效果的关键组合。本文还讨论了小细胞肺癌癌症的化学治疗,即对肿瘤细胞的作用原理。然而,这种化疗仍然毒性很大,并会导致一些危及生命的副作用。有必要在治疗开始后立即评估化疗的有效性,以平衡益处和风险。结论:目前正在寻找毒性较低但有效的化合物,这是为癌症患者提供高质量医疗和药物护理的医疗保健关键问题。所研究的病理学的化疗需要高成本;因此,有必要对癌症小细胞化疗的处方进行药物经济学评估,以比较其治疗成本和疗效
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research Results in Pharmacology
Research Results in Pharmacology Medicine-Pharmacology (medical)
CiteScore
1.50
自引率
0.00%
发文量
32
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信